Multicenter phase II trial of doxorubicin and cyclophosphamide (AC) followed by weekly docetaxel (T) as neoadjuvant treatment for operable stage II and IIIA breast cancer patients

Trial Profile

Multicenter phase II trial of doxorubicin and cyclophosphamide (AC) followed by weekly docetaxel (T) as neoadjuvant treatment for operable stage II and IIIA breast cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2006

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top